Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
REDWOOD CITY, Calif. - Revolution Medicines, Inc. (NASDAQ:RVMD), a $7.6 billion market cap biotech company with a "Fair" financial health score according to InvestingPro, announced encouraging clinical data for its experimental cancer drug daraxonrasib in treating metastatic pancreatic ductal adenocarcinoma (PDAC), according to a press release issued Wednesday.
Long-term follow-up data showed that for patients with second-line RAS mutant PDAC receiving daraxonrasib monotherapy, the confirmed objective response rate was 29% with disease control achieved in 95% of patients. The median progression-free survival was 8.1 months, while median overall survival reached 15.6 months with a median follow-up of 16.7 months. With analysts setting price targets between $56 and $99, InvestingPro subscribers can access 8 additional key insights about Revolution Medicines’ financial outlook and market position.
In first-line treatment, daraxonrasib monotherapy demonstrated a 47% objective response rate and 89% disease control rate among 38 evaluable patients. When combined with standard chemotherapy in the first-line setting, the drug showed a 55% response rate and 90% disease control rate.
The company reported that daraxonrasib was generally well-tolerated as both a monotherapy and in combination with chemotherapy, with safety profiles consistent with previously reported data.
Based on these results, Revolution Medicines plans to initiate a three-arm Phase 3 trial called RASolute 303 in the fourth quarter of 2025. The study will evaluate daraxonrasib both as monotherapy and in combination with chemotherapy against standard chemotherapy in first-line metastatic PDAC.
The company’s ongoing Phase 3 trial of daraxonrasib monotherapy in second-line PDAC is expected to complete enrollment this year with data anticipated in 2026.
Pancreatic cancer remains one of the most lethal malignancies, with approximately 60,000 new diagnoses expected annually in the U.S. and a five-year survival rate of only about 3% for metastatic disease, according to statistics cited in the press release. Revolution Medicines maintains a strong financial position with a current ratio of 11.79 and more cash than debt on its balance sheet, though InvestingPro analysis indicates the company is currently trading near its Fair Value.
In other recent news, Revolution Medicines reported its Q2 2025 earnings, which showed a larger-than-expected loss. The company posted an earnings per share (EPS) of -$1.31, missing the forecast of -$1.12. Revenue expectations were also unmet, with actual revenue coming in at $0 against an anticipated $30.59 million. Truist Securities initiated coverage on Revolution Medicines with a Buy rating and a price target of $99.00, emphasizing the company’s focus on RAS mutations in cancer treatment. Oppenheimer reiterated its Outperform rating with a $75.00 price target after discussions with company management, noting that initial data from the daraxonrasib RASolute-302 study is expected in 2026. Piper Sandler also began coverage with an Overweight rating and a $75.00 price target, highlighting the potential of Revolution’s drug, daraxonrasib, in treating metastatic pancreatic ductal adenocarcinoma. These developments reflect the company’s ongoing efforts and challenges in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.